173 related articles for article (PubMed ID: 36983631)
1. Advances in Cystic Fibrosis Research in Qatar: A Commentary.
Hammoudeh S; Janahi IA
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983631
[TBL] [Abstract][Full Text] [Related]
2. Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions.
Hammoudeh S; Gadelhak W; AbdulWahab A; Al-Langawi M; Janahi IA
Multidiscip Respir Med; 2019; 14():29. PubMed ID: 31583102
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of the cystic fibrosis phenotype in a large kindred family in Qatar with cystic fibrosis mutation (I1234V).
Abdul Wahab A; Al Thani G; Dawod ST; Kambouris M; Al Hamed M
J Trop Pediatr; 2001 Apr; 47(2):110-2. PubMed ID: 11336127
[TBL] [Abstract][Full Text] [Related]
4. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis mutation I1234V in a Qatari lady.
Wahab AA
J Trop Pediatr; 2003 Feb; 49(1):54-5. PubMed ID: 12630722
[TBL] [Abstract][Full Text] [Related]
6. Faecal elastase-1 concentration in cystic fibrosis patients with CFTR I1234V mutation.
Abdel Rahman H; Abdul Wahab A; Abdel Rahman MO; Mostafa OA
Acta Paediatr; 2006 Sep; 95(9):1066-9. PubMed ID: 16938751
[TBL] [Abstract][Full Text] [Related]
7. First report of the cystic fibrosis transmembrane conductance regulator mutation c.1521_1523delCTT (p. Phe508del) in two Qatari patients with cystic fibrosis.
AbdulWahab A; AlNaimi A; Habra B; Janahi I
Qatar Med J; 2021; 2021(1):24. PubMed ID: 34377682
[TBL] [Abstract][Full Text] [Related]
8. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
9. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
10. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
11. Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.
Moshirfar M; Brown AH; Sulit CA; Corbin WM; Ronquillo YC; Hoopes PC
Int Med Case Rep J; 2022; 15():647-656. PubMed ID: 36388243
[TBL] [Abstract][Full Text] [Related]
12. Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention.
Molinski SV; Gonska T; Huan LJ; Baskin B; Janahi IA; Ray PN; Bear CE
Genet Med; 2014 Aug; 16(8):625-32. PubMed ID: 24556927
[TBL] [Abstract][Full Text] [Related]
13. A Rare Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation Associated With Typical Cystic Fibrosis in an Arab Child.
Mathew A; Dirawi M; Abou Tayoun A; Popatia R
Cureus; 2021 Feb; 13(2):e13526. PubMed ID: 33786233
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
15. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
16. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
[TBL] [Abstract][Full Text] [Related]
17. Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator.
Mekus F; Ballmann M; Bronsveld I; Dörk T; Bijman J; Tümmler B; Veeze HJ
Hum Genet; 1998 May; 102(5):582-6. PubMed ID: 9654209
[TBL] [Abstract][Full Text] [Related]
18. The future of cystic fibrosis care: a global perspective.
Bell SC; Mall MA; Gutierrez H; Macek M; Madge S; Davies JC; Burgel PR; Tullis E; Castaños C; Castellani C; Byrnes CA; Cathcart F; Chotirmall SH; Cosgriff R; Eichler I; Fajac I; Goss CH; Drevinek P; Farrell PM; Gravelle AM; Havermans T; Mayer-Hamblett N; Kashirskaya N; Kerem E; Mathew JL; McKone EF; Naehrlich L; Nasr SZ; Oates GR; O'Neill C; Pypops U; Raraigh KS; Rowe SM; Southern KW; Sivam S; Stephenson AL; Zampoli M; Ratjen F
Lancet Respir Med; 2020 Jan; 8(1):65-124. PubMed ID: 31570318
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.
Sloane PA; Rowe SM
Curr Opin Pulm Med; 2010 Nov; 16(6):591-7. PubMed ID: 20829696
[TBL] [Abstract][Full Text] [Related]
20. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
